
MilliporeSigma Develops New CRISPR Technology
The company developed proxy-CRISPR which provides access to previously unreachable areas of the genome.
On May 17, 2017 MilliporeSigma announced that it has developed a new CRISPR genome-editing tool. This new technique, called proxy-CRISPR, provides access to previously unreachable areas of the genome. Most natural CRISPR systems, found in bacteria, cannot work in human cells without significant re-engineering. Proxy-CRISPR increases their usability without the need to re-engineer native CRISPR proteins, the company noted in a
MilliporeSigma's research on proxy-CRISPR,
The new technology is an addition to MilliporeSigma's existing CRISPR applications. The company's next suite of genome editing tools for the research community, to be launched later in 2017, will include novel and modified versions of Cas and Cas-like proteins.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.